Filtered By:
Cancer: Endometrial Cancer

This page shows you your search results in order of date. This is page number 13.

Order by Relevance | Date

Total 190 results found since Jan 2013.

908P * NUCLEAR EXPRESSION OF BCL10 HAS A ROLE IN THE REGULATION OF CELL GROWTH OF OVARIAN CANCER THROUGH THE ACTIVATION OF NF-{kappa}B-DEPENDENT CYCLIN D1 SIGNALING
Conclusions: Our findings indicate that nuclear BCL10 plays an important role in controlling the growth and progression of ovarian cancer cells through NF-B dependent cyclin D1 regulation.Disclosure: All authors have declared no conflicts of interest.
Source: Annals of Oncology - September 24, 2014 Category: Cancer & Oncology Authors: Kuo, S., Chou, C., Chen, R., Cheng, A. Tags: gynaecological cancers Source Type: research

MiR‐506 inhibits multiple targets in the epithelial‐to‐mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer
In this study, we provide evidence that miR‐506 simultaneously suppresses vimentin and N‐cad. The knockdown of vimentin using siRNA reversed EMT, suppressed cell migration and invasion, and increased E‐cad expression on cell membrane in epithelial ovarian cancer (EOC) cells. In a set of tissue microarrays that included 204 EOCs of all major subtypes (e.g., serous, endometrioid, clear cell, and mucinous), miR‐506 was positively correlated with E‐cad and negatively correlated with vimentin and N‐cad in all subtypes of EOC. A high level of miR‐506 was positively associated with early FIGO stage and longer surviv...
Source: The Journal of Pathology - September 17, 2014 Category: Pathology Authors: Yan Sun, Limei Hu, Hong Zheng, Marina Bagnoli, Yuhong Guo, Rajesha Rupaimoole, Cristian Rodriguez‐Aguayo, Gabriel Lopez‐Berestein, Ping Ji, Kexin Chen, Anil K. Sood, Delia Mezzanzanica, Jinsong Liu, Baocun Sun, Wei Zhang Tags: Original Article Source Type: research

Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
Conclusions: Our results suggest that olaparib, a PARP inhibitor, is effective on certain endometrial cancer cell lines. Inactivation of PTEN might not affect the DNA repair function. Predictive biomarkers are warranted to utilize olaparib in endometrial cancer.
Source: Epidemiologic Perspectives and Innovations - March 13, 2014 Category: Epidemiology Authors: Aki MiyasakaKatsutoshi OdaYuji IkedaOsamu Wada-HiraikeTomoko KashiyamaAtsushi EnomotoNoriko HosoyaTakahiro KosoTomohiko FukudaKanako InabaKenbun SoneYuriko UeharaReiko KurikawaKazunori NagasakaYoko MatsumotoTakahide ArimotoShunsuke NakagawaHiroyuki Kuramo Source Type: research

A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation
Background: Ovarian cancer is now recognized as a number of distinct diseases primarily defined by histological subtype. Both clear cell ovarian carcinomas (CCC) and ovarian endometrioid carcinomas (EC) may arise from endometriosis and frequently harbor mutations in the ARID1A tumor suppressor gene. We studied the influence of histological subtype on protein expression with reverse phase protein array (RPPA) and assessed proteomic changes associated with ARID1A mutation/BAF250a expression in EC and CCC. Methods: Immunohistochemistry (IHC) for BAF250a expression was performed on 127 chemotherapy-naive ovarian carcinomas (33...
Source: BMC Cancer - February 22, 2014 Category: Cancer & Oncology Authors: Kimberly WiegandBryan HennessySamuel LeungYemin WangZhenlin JuMollianne McGahrenSteve KallogerSarah FinlaysonKatherine Stemke-HaleYiling LuFan ZhangMichael AnglesioBlake GilksGordon MillsDavid HuntsmanMark Carey Source Type: research

FOXA1 promotes tumor cell proliferation through AR involving the Notch pathway in endometrial cancer
Conclusions: These results suggest that FOXA1 promotes cell proliferation by AR and activates Notch pathway. It indicated that FOXA1 and AR may serve as potential gene therapy in EC.
Source: BMC Cancer - February 11, 2014 Category: Cancer & Oncology Authors: Meiting QiuWei BaoJingyun WangTingting YangXiaoying HeYun LiaoXiaoping Wan Source Type: research

MicroRNA‐106b modulates epithelial–mesenchymal transition by targeting TWIST1 in invasive endometrial cancer cell lines
In this study, we sought to explore the role of TWIST1 in inducing EMT in representative type II EC cell lines, and to determine the miRNAs involved in regulating TWIST1 gene expression. Functional analysis suggested that TWIST1 contributes to the EMT phenotypes of EC cells, as evidenced by the acquisition of fibroblast‐like properties, enhanced invasiveness, and induction of an EN‐switch (downregulation of epithelial marker E‐cadherin and upregulation of mesenchymal marker N‐cadherin). Conversely, silencing of TWIST1 by siRNA inhibited cell invasion and the mesenchymal phenotype, which was accompanied by a reversi...
Source: Molecular Carcinogenesis - September 3, 2013 Category: Molecular Biology Authors: Peixin Dong, Masanori Kaneuchi, Hidemichi Watari, Satoko Sudo, Noriaki Sakuragi Tags: Research Article Source Type: research

EZH2 gene silenced by siRNA suppresses the growth and invasion of endometrial carcinoma cells.
CONCLUSION: EZH2 expression is increased in endometrial carcinoma tissues. Knocking down EZH2 expression suppresses the cell growth, cell cycle transition and cell invasion by downregulated E2F1 and MMP9, and upregulated tumor suppressor p21 expression. PMID: 23803199 [PubMed - in process]
Source: Journal of Southern Medical University - June 20, 2013 Category: Universities & Medical Training Authors: Leng LZ, Huang QT, Dong YN, Yu H, Tian Y, Peng GQ Tags: Nan Fang Yi Ke Da Xue Xue Bao Source Type: research

Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the invasiveness of endometrial cancer cells through the GnRH-I receptor and mitogen-activated protein kinase (MAPK)-dependent activation of matrix metalloproteinase (MMP)-2
Conclusion: Our study indicates that GnRH-II agonist promoted cell motility of endometrial cancer cells through the GnRH-I receptor via the phosphorylation of ERK1/2 and JNK, and the subsequent, MAPK-dependent activation of MMP-2. Our findings represent a new concept regarding the mechanism of GnRH-II-induced cell motility in endometrial cancer cells and suggest the possibility of exploring GnRH-II as a potential therapeutic target for the treatment of human endometrial cancer.
Source: BMC Cancer - June 20, 2013 Category: Cancer & Oncology Authors: Hsien-Ming WuHsin-Shih WangHong-Yuan HuangChyong-Huey LaiChyi-Long LeeYung-Kuei SoongPeter Leung Source Type: research

The PRB-dependent FOXO1/IGFBP-1 axis is essential for progestin to inhibit endometrial epithelial growth
Abstract: Progestin inhibits the growth of normal and cancerous endometria via the progesterone receptor (PR), but the distinct functions and signalings of PR subtypes have not been fully understood. The aim of the present study was to dissect the key pathways of progestin to inhibit endometrial epithelial growth. Immortalized endometrial epithelial cells (EM-E6/E7/TERT) with stable PRA or PRB expression were established and used for the experiments. In vitro growth inhibition by progestin was mainly observed in EM-E6/E7/TERT cells with PRB rather than those with PRA. RT-PCR assay confirmed that FOXO1, a key gene for proge...
Source: Cancer Letters - May 13, 2013 Category: Cancer & Oncology Authors: Mitsuhiro Nakamura, Masahiro Takakura, Reina Fujii, Yoshiko Maida, Yukiko Bono, Yasunari Mizumoto, Xian Zhang, Tohru Kiyono, Satoru Kyo Tags: Research Articles Source Type: research

Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer.
CONCLUSIONS: By taking this integrative approach to target discovery we have streamlined the translation of high-resolution genomic data into pre-clinical in vitro studies, resulting in the identification of a number of genes that may be specifically targeted for the treatment of ovarian tumors. PMID: 23362323 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - January 29, 2013 Category: Cancer & Oncology Authors: Davis SJ, Sheppard KE, Pearson RB, Campbell IG, Gorringe KL, Simpson K Tags: Clin Cancer Res Source Type: research